Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal… Read more
Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Laboratories rely on high-quality reference standards of Niraparib and its associated compounds to ensure precise analytical results and regulatory compliance. This category includes process-related impurities, synthetic intermediates, degradation products, and metabolites essential for comprehensive impurity profiling. Additionally, stable isotope labelled compounds are available to support accurate quantification in bioanalytical methods, such as LC-MS/MS, during pharmacokinetic and drug metabolism studies. By utilizing these characterized materials, researchers can effectively perform method validation, stability testing, and rigorous quality control, ensuring the safety and efficacy of pharmaceutical products in alignment with international guidelines for drug development.